{"title":"噪声和药物性听力损失的药物预防:抗氧化剂耳保护的发展现状","authors":"K. Campbell","doi":"10.1044/HHD15.1.15","DOIUrl":null,"url":null,"abstract":"Abstract Within the next decade audiologists will be working with patients and physicians in selecting and monitoring pharmacologic otoprotective agents against drug and noise induced hearing loss either for research or clinic applications or both. Currently, several of these agents are in clinical trials, although none yet have Food and Drug Administration approval for clinical use.","PeriodicalId":90676,"journal":{"name":"Perspectives on hearing and hearing disorders. Research and research diagnostics","volume":"17 1","pages":"15-24"},"PeriodicalIF":0.0000,"publicationDate":"2011-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pharmacologic Prevention of Noise and Drug-induced Hearing Loss: Current State of Development of Antioxidant Otoprotection\",\"authors\":\"K. Campbell\",\"doi\":\"10.1044/HHD15.1.15\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Within the next decade audiologists will be working with patients and physicians in selecting and monitoring pharmacologic otoprotective agents against drug and noise induced hearing loss either for research or clinic applications or both. Currently, several of these agents are in clinical trials, although none yet have Food and Drug Administration approval for clinical use.\",\"PeriodicalId\":90676,\"journal\":{\"name\":\"Perspectives on hearing and hearing disorders. Research and research diagnostics\",\"volume\":\"17 1\",\"pages\":\"15-24\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Perspectives on hearing and hearing disorders. Research and research diagnostics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1044/HHD15.1.15\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Perspectives on hearing and hearing disorders. Research and research diagnostics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1044/HHD15.1.15","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Pharmacologic Prevention of Noise and Drug-induced Hearing Loss: Current State of Development of Antioxidant Otoprotection
Abstract Within the next decade audiologists will be working with patients and physicians in selecting and monitoring pharmacologic otoprotective agents against drug and noise induced hearing loss either for research or clinic applications or both. Currently, several of these agents are in clinical trials, although none yet have Food and Drug Administration approval for clinical use.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
